April 17 (Reuters) - Channel Therapeutics Corp CHRO.A:
LIGAND SUBSIDIARY PELTHOS THERAPEUTICS TO COMBINE WITH CHANNEL THERAPEUTICS
CHANNEL THERAPEUTICS CORP - PROPOSED TRANSACTION WILL RAISE $50 MILLION IN EQUITY CAPITAL
CHANNEL THERAPEUTICS CORP - LIGAND IS ENTITLED TO A 13% ROYALTY ON WORLDWIDE SALES OF ZELSUVMI
CHANNEL THERAPEUTICS CORP -COMBINED CO TO OPERATE UNDER NAME PELTHOS THERAPEUTICS INC., TRADE ON NYSE AMERICAN EXCHANGE UNDER TICKER PTHS
CHANNEL THERAPEUTICS CORP - UPON COMPLETION OF DEAL, PLESHA TO BECOME CEO OF COMBINED CO AND KNUETTEL TO BECOME CFO
Source text: ID:nGNX3XSQny
Further company coverage: CHRO.A
((Reuters.Briefs@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。